Indeed, GLP-1 RA users in our cohort exhibited more frequent risk factors for pancreatic cancer—including older age, obesity, type 2 diabetes, and prior gastrointestinal disorders—suggesting a background of increased vulnerability. Here, GLP1R is linked to pancreatic neoplasm.